AI x Bio Summit: The Co-Founder of Kernal Bio describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body

blonca9
Jul 25, 2024
1 min read

Yusuf Erkul explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

AI x Bio Summit: The Co-Founder of Kernal Bio describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight